# Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)

> **NCT04501380** · PHASE2 · UNKNOWN · sponsor: **Bradley Connor** · enrollment: 30 (estimated)

## Conditions studied

- Small Intestinal Bacterial Overgrowth
- Gastrointestinal Disease
- Gastrointestinal Infection

## Interventions

- **DRUG:** AEMCOLO (Rifamycin SV MMX)

## Key facts

- **NCT ID:** NCT04501380
- **Lead sponsor:** Bradley Connor
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-30
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501380, "Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04501380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*